Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27


Accelerated Venovenous Hemofiltration as a Transitional Renal Replacement Therapy in the Intensive Care Unit.

Allegretti AS, Endres P, Parris T, Zhao S, May M, Sylvia-Reardon M, Bezreh N, Culbert-Costley R, Ananian L, Roberts RJ, Lopez N, Charytan DM, Tolkoff-Rubin N.

Am J Nephrol. 2020 Feb 25:1-9. doi: 10.1159/000506412. [Epub ahead of print]


Kidney Function Decline among Black Patients with Sickle Cell Trait and Sickle Cell Disease: An Observational Cohort Study.

Olaniran KO, Allegretti AS, Zhao SH, Achebe MM, Eneanya ND, Thadhani RI, Nigwekar SU, Kalim S.

J Am Soc Nephrol. 2020 Feb;31(2):393-404. doi: 10.1681/ASN.2019050502. Epub 2019 Dec 6.


Validity of International Classification of Diseases Codes for Sickle Cell Trait and Sickle Cell Disease.

Olaniran KO, Seethapathy H, Zhao SH, Allegretti AS, Kalim S, Nigwekar SU.

J Gen Intern Med. 2019 Nov 19. doi: 10.1007/s11606-019-05555-w. [Epub ahead of print] No abstract available.


Fluid assessment in dialysis patients by point-of-care magnetic relaxometry.

Colucci LA, Corapi KM, Li M, Parada XV, Allegretti AS, Lin HY, Ausiello DA, Rosen MS, Cima MJ.

Sci Transl Med. 2019 Jul 24;11(502). pii: eaau1749. doi: 10.1126/scitranslmed.aau1749.


Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement.

Allegretti AS, Frenk NE, Li DK, Seethapathy H, Vela Parada XF, Long J, Endres P, Pratt DS, Chung RT, Ganguli S, Irani Z, Yamada K.

PLoS One. 2019 May 23;14(5):e0217442. doi: 10.1371/journal.pone.0217442. eCollection 2019.


Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.

Allegretti AS, Zhang W, Zhou W, Thurber TK, Rigby SP, Bowman-Stroud C, Trescoli C, Serusclat P, Freeman MW, Halvorsen YC.

Am J Kidney Dis. 2019 Sep;74(3):328-337. doi: 10.1053/j.ajkd.2019.03.417. Epub 2019 May 14.


Blood Microbiome Profile in CKD : A Pilot Study.

Shah NB, Allegretti AS, Nigwekar SU, Kalim S, Zhao S, Lelouvier B, Servant F, Serena G, Thadhani RI, Raj DS, Fasano A.

Clin J Am Soc Nephrol. 2019 May 7;14(5):692-701. doi: 10.2215/CJN.12161018. Epub 2019 Apr 8.


Cardiovascular Outcomes in African Americans with Sickle Cell Trait and Chronic Kidney Disease.

Olaniran KO, Eneanya ND, Allegretti AS, Zhao SH, Achebe MM, Thadhani RI.

Am J Nephrol. 2019;49(2):93-102. doi: 10.1159/000496058. Epub 2019 Jan 9.


Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease: A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group.

Verberne WR, Das-Gupta Z, Allegretti AS, Bart HAJ, van Biesen W, García-García G, Gibbons E, Parra E, Hemmelder MH, Jager KJ, Ketteler M, Roberts C, Al Rohani M, Salt MJ, Stopper A, Terkivatan T, Tuttle KR, Yang CW, Wheeler DC, Bos WJW.

Am J Kidney Dis. 2019 Mar;73(3):372-384. doi: 10.1053/j.ajkd.2018.10.007. Epub 2018 Dec 20.


Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis.

Allegretti AS, Vela Parada X, Ortiz GA, Long J, Krinsky S, Zhao S, Fuchs BC, Sojoodi M, Zhang D, Karumanchi SA, Kalim S, Nigwekar SU, Thadhani RI, Parikh SM, Chung RT.

Hepatology. 2019 Feb;69(2):729-741. doi: 10.1002/hep.30230. Epub 2019 Jan 4.


Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.

Allegretti AS, Israelsen M, Krag A, Jovani M, Goldin AH, Schulman AR, Winter RW, Gluud LL.

Cochrane Database Syst Rev. 2017 Jun 14;6:CD005162. doi: 10.1002/14651858.CD005162.pub4. Review.


Epidemiology: Chronic disease, cancer, and exercise - a common link.

Allegretti AS, Thadhani RI.

Nat Rev Nephrol. 2018 May;14(5):288-290. doi: 10.1038/nrneph.2018.24. Epub 2018 Mar 26. No abstract available.


Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT.

Allegretti AS, Parada XV, Eneanya ND, Gilligan H, Xu D, Zhao S, Dienstag JL, Chung RT, Thadhani RI.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):16-25. doi: 10.2215/CJN.03610417. Epub 2017 Nov 9.


Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment.

Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M.

Clin Microbiol Infect. 2018 Jul;24(7):780.e1-780.e3. doi: 10.1016/j.cmi.2017.10.022. Epub 2017 Nov 11.


Classifying Fecal Microbiota Transplantation Failure: An Observational Study Examining Timing and Characteristics of Fecal Microbiota Transplantation Failures.

Allegretti JR, Allegretti AS, Phelps E, Xu H, Fischer M, Kassam Z.

Clin Gastroenterol Hepatol. 2018 Nov;16(11):1832-1833. doi: 10.1016/j.cgh.2017.10.031. Epub 2017 Nov 16.


Terlipressin versus other vasoactive drugs for hepatorenal syndrome.

Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, Gluud LL.

Cochrane Database Syst Rev. 2017 Sep 27;9:CD011532. doi: 10.1002/14651858.CD011532.pub2. Review.


Case 12-2017 - A 34-Year-Old Man with Nephropathy.

Sise ME, Lo GC, Goldstein RH, Allegretti AS, Masia R.

N Engl J Med. 2017 Apr 20;376(16):1575-1585. doi: 10.1056/NEJMcpc1616395. No abstract available.


Siglec-7 as a Novel Biomarker to Predict Mortality in Decompensated Cirrhosis and Acute Kidney Injury.

Allegretti AS, Ortiz G, Kalim S, Wibecan J, Zhang D, Shan HY, Xu D, Chung RT, Karumanchi SA, Thadhani RI.

Dig Dis Sci. 2016 Dec;61(12):3609-3620. Epub 2016 Sep 21.


Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis.

Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, Thadhani RI, Irani Z.

Am J Kidney Dis. 2016 Sep;68(3):381-91. doi: 10.1053/j.ajkd.2016.02.041. Epub 2016 Mar 16.


Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study.

Allegretti AS, Ortiz G, Wenger J, Deferio JJ, Wibecan J, Kalim S, Tamez H, Chung RT, Karumanchi SA, Thadhani RI.

Int J Nephrol. 2015;2015:108139. doi: 10.1155/2015/108139. Epub 2015 Jul 22.


Shear wave elastography in chronic kidney disease: a pilot experience in native kidneys.

Samir AE, Allegretti AS, Zhu Q, Dhyani M, Anvari A, Sullivan DA, Trottier CA, Dougherty S, Williams WW, Babitt JL, Wenger J, Thadhani RI, Lin HY.

BMC Nephrol. 2015 Jul 31;16:119. doi: 10.1186/s12882-015-0120-7.


Perspectives of continuous renal replacement therapy in the intensive care unit: a paired survey study of patient, physician, and nurse views.

Allegretti AS, Hundemer G, Chorghade R, Cosgrove K, Bajwa E, Bhan I.

BMC Nephrol. 2015 Jul 14;16:105. doi: 10.1186/s12882-015-0086-5.


The effect of bicarbonate administration via continuous venovenous hemofiltration on acid-base parameters in ventilated patients.

Allegretti AS, Flythe JE, Benda V, Robinson ES, Charytan DM.

Biomed Res Int. 2015;2015:901590. doi: 10.1155/2015/901590. Epub 2015 Jan 8.


Counseling potential donors to the risk of ESRD after kidney donation: glass half-full or half-empty?

Allegretti AS, Yeung MY, Riella LV.

Am J Transplant. 2014 Oct;14(10):2434-5. doi: 10.1111/ajt.12861. Epub 2014 Aug 28. No abstract available.


Calciphylaxis: a rare but fatal delayed complication of Roux-en-Y gastric bypass surgery.

Allegretti AS, Nazarian RM, Goverman J, Nigwekar SU.

Am J Kidney Dis. 2014 Aug;64(2):274-7. doi: 10.1053/j.ajkd.2014.02.029. Epub 2014 Apr 29.


Continuous renal replacement therapy outcomes in acute kidney injury and end-stage renal disease: a cohort study.

Allegretti AS, Steele DJ, David-Kasdan JA, Bajwa E, Niles JL, Bhan I.

Crit Care. 2013 Jun 20;17(3):R109. doi: 10.1186/cc12780.


Intravenous moderate-dose bumetanide continuous infusion and severe musculoskeletal pain.

Vaduganathan M, Allegretti AS, Manchette AM, Patel SS, Olson KR, Bazari H.

Int J Cardiol. 2013 Sep 20;168(1):e29-31. doi: 10.1016/j.ijcard.2013.05.081. Epub 2013 May 30. No abstract available.


Supplemental Content

Loading ...
Support Center